These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27665536)

  • 21. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study.
    Tanaka Y; Escobar R; Upadhyaya HP
    Atten Defic Hyperact Disord; 2017 Jun; 9(2):113-120. PubMed ID: 28058589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials.
    Ravishankar V; Chowdappa SV; Benegal V; Muralidharan K
    Asian J Psychiatr; 2016 Dec; 24():53-58. PubMed ID: 27931908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
    Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Mayfield-Jorgensen ML; March JS; Kollins SH; Murray DW; Ravi H; Greenhill LL; Kotler LA; Paykina N; Biggins P; Stoner J
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):175-85. PubMed ID: 17489712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
    Yang R; Gao W; Li R; Zhao Z
    Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wietecha LA; Williams DW; Herbert M; Melmed RD; Greenbaum M; Schuh K
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):719-30. PubMed ID: 20035590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
    Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
    J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
    Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
    J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of 5-HT
    Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S
    Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
    Gau SS; Shang CY
    Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.
    Maziade M; Rouleau N; Lee B; Rogers A; Davis L; Dickson R
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):709-18. PubMed ID: 20035589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
    Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.